Nervous System News and Research

Latest Nervous System News and Research

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Biovail Corporation today announced financial results for the three-month and 12-month periods ending December 31, 2009.

25 Feb 2010

Biovail declares quarterly cash dividend of US$0.09 per share

Biovail Corporation today announced that the Company’s Board of Directors has declared a quarterly cash dividend of US$0.09 per share payable on April 5, 2010 to shareholders of record at the close of business March 8, 2010. The ex-dividend date is March 4, 2010.

25 Feb 2010

IOS Press announces the 20th anniversary of Restorative Neurology and Neuroscience journal

IOS Press is pleased to announce the 20th anniversary of the peer-reviewed journal Restorative Neurology and Neuroscience. Since founded in 1989 by pioneering neuroscientist Donald G. Stein, RNN has focused on the emerging field of brain plasticity, repair and rehabilitation and has published not only numerous original scientific publications, but also review papers in basic research (animal experiments, in vitro studies) and in the clinical sciences.

25 Feb 2010

WSU Boonshoft School of Medicine and Miami Valley Hospital form new neuroscience institute

Wright State University Boonshoft School of Medicine and Miami Valley Hospital announced today the formation of the Wright State University & Premier Health Partners Neuroscience Institute to speed the transfer of research discoveries from bench to bedside, improving the diagnosis and treatment of neurological disorders such as stroke. Ohio Governor Ted Strickland and Chancellor of the Ohio Board of Regents Eric Fingerhut joined Wright State University and Miami Valley Hospital officials in making the announcement.

25 Feb 2010

Transplanting genetically modified adult stem cells into injured spinal cord increases movement recovery

Researchers at UTHealth have demonstrated in rats that transplanting genetically modified adult stem cells into an injured spinal cord can help restore the electrical pathways associated with movement. The results are published in the Feb. 24 issue of the Journal of Neuroscience.

25 Feb 2010

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin.

25 Feb 2010

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Arena Pharmaceuticals, Inc. announced today that its New Drug Application (NDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss, has been accepted for filing by the US Food and Drug Administration (FDA). Arena submitted the lorcaserin NDA on December 22, 2009, and expects to learn the Prescription Drug User Fee Act (PDUFA) date in the next few weeks. The PDUFA date is the target date for the FDA to complete its review of an NDA.

24 Feb 2010

Genetic link between schizophrenia and autism may help study effectiveness of drugs for both illnesses

A genetic link between schizophrenia and autism is enabling researchers to study the effectiveness of drugs used to treat both illnesses.

24 Feb 2010

Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the trial and that Catalyst will contribute approximately $2.5 million in resources as part of the estimated $10 million trial cost.

23 Feb 2010

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).

23 Feb 2010

Cephalon to acquire Ception Therapeutics following positive clinical study of eosinophilic asthma

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exercised its option to acquire Ception Therapeutics, Inc., following receipt of positive data from a clinical study in adults with eosinophilic asthma.

23 Feb 2010

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2009.

23 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

AAN guideline evaluates drugs’ safety and efficacy for treatment of muscle cramps

A new guideline from the American Academy of Neurology recommends that the drug quinine, although effective, should be avoided for treatment of routine muscle cramps due to uncommon but serious side effects.

23 Feb 2010

Cash-strapped school districts are making mistake by cutting music from K-12 curriculum: Neuroscientist

At an 11 a.m. press briefing, Saturday, Feb. 20, at the American Association for the Advancement of Science annual meeting, a Northwestern University neuroscientist will argue that music training has profound effects that shape the sensory system and should be a mainstay of K-12 education.

22 Feb 2010

Separate Complaints filed against Biovail by S.A.C. Capital Advisors and Gradient Analytics

Biovail Corporation today acknowledged that separate Complaints have been filed against the Company by S.A.C. Capital Advisors, LLC and Gradient Analytics, Inc. The Complaints, filed in the U.S. District Court for the District of Connecticut and the U.S. District Court for the District of Arizona, respectively, allege malicious prosecution related to Biovail’s 2006 filing of a lawsuit against them and others.

21 Feb 2010

Sepracor to merge with Dainippon Sumitomo Pharma America

Sepracor Inc. and Dainippon Sumitomo Pharma Co., Ltd. (DSP) today announce the resignation of Adrian Adams as President and Chief Executive Officer and Director of Sepracor and as Executive Officer of DSP, effective immediately, and the appointment of Saburo Hamanaka as Chairman of Sepracor and Executive Officer of DSP. Sepracor and DSP also announce the planned merger of Sepracor and DSP’s subsidiary, Dainippon Sumitomo Pharma America, Inc. (DSPA), to be completed on April 1, 2010, with Sepracor as the surviving company.

19 Feb 2010

University of California researchers awarded AAN's 2010 Potamkin Prize

The American Academy of Neurology (AAN) is awarding its 2010 Potamkin Prize to two researchers for their work in Alzheimer's disease and frontotemporal lobar degeneration (FTLD), a common type of dementia. Bruce L. Miller, MD, and Lennart Mucke, MD, both of the University of California San Francisco will receive the Award during the AAN's 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists with more than 2,000 presentations made on the latest advances in neurologic research.

19 Feb 2010

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

PsychoGenics Inc. today announced the establishment of an exclusive alliance with Dr. Jan Kehr, an internationally recognized expert in experimental neuropharmacology, to provide specialized microdialysis services to complement PsychoGenics’ in vivo testing capabilities.

19 Feb 2010

SRI International establishes new Neurodegenerative Diseases Research Program

SRI International, an independent nonprofit research and development institute, announced today that a new Neurodegenerative Diseases Research Program has been established within its Center for Health Sciences. This new SRI group of neuroscientists and researchers working at the cutting edge of science brings $6.2 million of funding from the National Institutes of Health (NIH), including the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Environmental Health Sciences (NIEHS), and National Institute of General Medical Sciences (NIGMS).

19 Feb 2010

Nervous System News and Research

Latest Nervous System News and Research

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Biovail declares quarterly cash dividend of US$0.09 per share

IOS Press announces the 20th anniversary of Restorative Neurology and Neuroscience journal

WSU Boonshoft School of Medicine and Miami Valley Hospital form new neuroscience institute

Transplanting genetically modified adult stem cells into injured spinal cord increases movement recovery

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Genetic link between schizophrenia and autism may help study effectiveness of drugs for both illnesses

Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Cephalon to acquire Ception Therapeutics following positive clinical study of eosinophilic asthma

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

AAN guideline evaluates drugs’ safety and efficacy for treatment of muscle cramps

Cash-strapped school districts are making mistake by cutting music from K-12 curriculum: Neuroscientist

Separate Complaints filed against Biovail by S.A.C. Capital Advisors and Gradient Analytics

Sepracor to merge with Dainippon Sumitomo Pharma America

University of California researchers awarded AAN's 2010 Potamkin Prize

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

SRI International establishes new Neurodegenerative Diseases Research Program

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Nervous System News and Research

Latest Nervous System News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in